
Kiromic BioPharma KRBP
Annual report 2024
added 02-14-2025
Kiromic BioPharma General and Administrative Expenses 2011-2026 | KRBP
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Kiromic BioPharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.85 M | 10.3 M | 17.2 M | 13.9 M | 14.1 M | 2.5 M | 1.76 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.2 M | 1.76 M | 9.81 M |
Quarterly General and Administrative Expenses Kiromic BioPharma
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.38 M | 2.22 M | - | 2.87 M | 2.33 M | 2.7 M | - | 4.61 M | 4.55 M | 4.44 M | - | 2.66 M | 2.31 M | 2.07 M | - | 1.19 M | 10.1 M | 825 K | - | 607 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 607 K | 3.06 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
AC Immune SA
ACIU
|
17.9 M | $ 2.72 | 7.51 % | $ 229 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.81 | 1.28 % | $ 4.42 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
argenx SE
ARGX
|
308 M | $ 840.28 | 1.7 % | $ 25 B | ||
|
Ascendis Pharma A/S
ASND
|
160 M | $ 234.99 | 0.02 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.33 | 0.79 % | $ 8.01 B | ||
|
Atea Pharmaceuticals
AVIR
|
48.8 M | $ 4.65 | 1.31 % | $ 392 M | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
BioVie
BIVI
|
8.57 M | $ 1.25 | - | $ 1.85 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.01 B | $ 62.62 | -0.48 % | $ 11.9 B | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Capricor Therapeutics
CAPR
|
12.8 M | $ 27.91 | 0.14 % | $ 747 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
CASI Pharmaceuticals
CASI
|
23.8 M | $ 0.8 | 5.68 % | $ 109 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | ||
|
Catalyst Biosciences
CBIO
|
14.7 M | $ 12.65 | 10.29 % | $ 833 M | ||
|
Axsome Therapeutics
AXSM
|
63.3 M | $ 169.95 | -2.75 % | $ 8.45 B | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
2.43 B | $ 195.13 | -0.62 % | $ 28.6 B | ||
|
Cellectis S.A.
CLLS
|
37.9 M | $ 3.98 | 0.51 % | $ 116 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | ||
|
Baudax Bio
BXRX
|
24.1 M | - | 0.59 % | $ 63 K | ||
|
Aptose Biosciences
APTO
|
11.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Cellectar Biosciences
CLRB
|
11.7 M | $ 3.36 | 3.07 % | $ 41.1 M |